olanzapine + risperidone + clozapine + quetiapine + haloperidol + perphenazine

This entry refers to a clinical research study (NCT00493233) conducted by the Centre for Addiction and Mental Health (CAMH) rather than a single pharmaceutical product. The study evaluated the effectiveness and safety of reducing antipsychotic polypharmacy to monotherapy in adult patients with schizophrenia. The medications involved—olanzapine, risperidone, clozapine, quetiapine, haloperidol, and perphenazine—represent a mix of typical (first-generation) and atypical (second-generation) antipsychotics. These small molecules primarily function as antagonists at the dopamine D2 and serotonin 5-HT2A receptors, though they also interact with various other neurotransmitter systems including adrenergic, histaminergic, and cholinergic receptors. The trial aimed to determine if patients could be successfully maintained on a single agent without clinical deterioration, thereby potentially reducing the cumulative side effect profile associated with multiple antipsychotic medications.

Brand names

Trilafon

Other names

Antipsychotic Polypharmacy in Schizophrenia StudyCAMH Polypharmacy Study